Luigi Bolondi
Luigi Bolondi
Professore ordinario di Medicina Interna
Email verificata su
Citata da
Citata da
Sorafenib in advanced hepatocellular carcinoma
JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.
T Livraghi, A Giorgio, G Marin, A Salmi, I De Sio, L Bolondi, M Pompili, ...
Radiology 197 (1), 101-108, 1995
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-update 2008
M Claudon, D Cosgrove, T Albrecht, L Bolondi, M Bosio, F Calliada, ...
Ultraschall in der Medizin-European Journal of Ultrasound 29 (01), 28-44, 2008
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma
L Gramantieri, M Ferracin, F Fornari, A Veronese, S Sabbioni, CG Liu, ...
Cancer research 67 (13), 6092-6099, 2007
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis
L Bolondi, S Sofia, S Siringo, S Gaiani, A Casali, G Zironi, F Piscaglia, ...
Gut 48 (2), 251-259, 2001
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
F Fornari, L Gramantieri, M Ferracin, A Veronese, S Sabbioni, GA Calin, ...
Oncogene 27 (43), 5651-5661, 2008
Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients
T Livraghi, L Bolondi, S Lazzaroni, G Marin, A Morabito, GL Rapaccini, ...
Cancer 69 (4), 925-929, 1992
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ...
Journal of hepatology 57 (4), 821-829, 2012
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
F Conti, F Buonfiglioli, A Scuteri, C Crespi, L Bolondi, P Caraceni, ...
Journal of hepatology 65 (4), 727-733, 2016
Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ...
New England Journal of Medicine 379 (1), 54-63, 2018
Guidelines for the use of contrast agents in ultrasound-january 2004
T Albrecht, M Blomley, L Bolondi, M Claudon, JM Correas, D Cosgrove, ...
Ultraschall in der Medizin-European Journal of Ultrasound 25 (04), 249-256, 2004
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
J Bruix, T Takayama, V Mazzaferro, GY Chau, J Yang, M Kudo, J Cai, ...
The lancet oncology 16 (13), 1344-1354, 2015
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization
JL Raoul, B Sangro, A Forner, V Mazzaferro, F Piscaglia, L Bolondi, ...
Cancer treatment reviews 37 (3), 212-220, 2011
Measurement of gastric emptying time by real-time ultrasonography
L Bolondi, M Bortolotti, V Santi, T Calletti, S Gaiani, G Labò
Gastroenterology 89 (4), 752-759, 1985
Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival
L Barbara, G Benzi, S Gaiani, F Fusconi, G Zironi, S Siringo, A Rigamonti, ...
Hepatology 16 (1), 132-137, 1992
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma
L Bolondi, S Gaiani, N Celli, R Golfieri, WF Grigioni, S Leoni, AM Venturi, ...
Hepatology 42 (1), 27-34, 2005
The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations
F Piscaglia, L Bolondi
Ultrasound in medicine & biology 32 (9), 1369-1375, 2006
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions
L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ...
Seminars in liver disease 32 (04), 348-359, 2012
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells
F Fornari, L Gramantieri, C Giovannini, A Veronese, M Ferracin, ...
Cancer research 69 (14), 5761-5767, 2009
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
F Fornari, M Milazzo, P Chieco, M Negrini, GA Calin, GL Grazi, D Pollutri, ...
Cancer research 70 (12), 5184-5193, 2010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20